NAD defers to FTC
This article was originally published in The Tan Sheet
Executive Summary
Council of Better Business Bureaus division is referring a dispute over ad claims for Aventis' Allegra to FTC and FDA after Aventis declined to participate in NAD's self-regulatory process, the watchdog group says. Benadryl Allergy marketer Pfizer challenged the ad, saying Aventis "mischaracterized the nature and efficacy" of Benadryl and "inappropriately expanded a durational claim of efficacy (on a per-dose basis) for its own Allegra product to a claim of overall superior efficacy," NAD says...
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.